Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology

17 Apr 2018

Abstract excerpt

Importance: To date, the benefit of genome-driven cancer therapy has not been quantified. Objective: We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approved genome-driven therapy from 2006 to 2018. Design, Setting, and Participants: Retrospective cross-sectional study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genomics and Rare Diseases
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29710180
DOI: 10.1001/jamaoncol.2018.1660

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologyPMID 29710180Read ↗

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer TherapeuticsSemantic proximity Read ↗

Advancements in Cancer TreatmentsSemantic proximity Read ↗

Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country.Semantic proximity Read ↗

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsSemantic proximity Read ↗

The Precision Medicine: Advancement and Transformation in Cancer TreatmentSemantic proximity Read ↗

Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort.Semantic proximity Read ↗

Incorporating tumor genomic profiling and drug screening through circulating tumor cell- derived organoids into clinical practice for the management of Gastrointestinal CancersSemantic proximity Read ↗

Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.Semantic proximity Read ↗

Comprehensive genomic profiling for patients with chemotherapy‐naïve advanced cancerSemantic proximity Read ↗

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncologySemantic proximity Read ↗

Personalized cancer care.Semantic proximity Read ↗

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.